Aaby, P; Martins, CL; Garly, ML; Andersen, A; Fisker, AB; Claesson, MH; Ravn, H; Rodrigues, A; Whittle, HC; Benn, CS (2014) Measles vaccination in the presence or absence of maternal measles antibody: Impact on child survival. Clinical infectious diseases . ISSN 1058-4838 DOI: 10.1093/cid/ciu354

Downloaded from: http://researchonline.lshtm.ac.uk/1726167/

DOI: 10.1093/cid/ciu354

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Supplementary table 1. Causes of death by verbal autopsy according to maternal antibody level at time of measles vaccination in Trial II

<table>
<thead>
<tr>
<th>Cause of death</th>
<th>Undetectable measles antibody level</th>
<th>Had maternal measles antibody</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory infection</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Diarrhoea, diarrhoea and vomiting</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Malaria, fever and anaemia</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Traditional ceremony (mongoloid child)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>No information (family moved)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>11</td>
<td>4</td>
</tr>
</tbody>
</table>
Supplementary Figure 1: Trial diagrams for the two early two-dose measles vaccination trials.

Trial I (1993-95)

Randomised to MV
N=150

Had detectable maternal antibody: N=27
Moved: 0
MV at 9 mo: 27 (100%)
Died: 0

Still in area: 17 (63%)
Moved: 10 (37%)
Died: 0

Had no detectable maternal antibody: N=123
Moved: 6 (5%)
MV at 9 mo: 114 (93%)
Died: 3 (2%)

Still in area: 49 (43%)
Moved: 52 (46%)
Died: 13 (11%)

Randomised to IPV
N=150

Had detectable maternal antibody: N=23
Moved: 3 (13%)
MV at 9 mo: 20 (87%)
Died: 0

Still in area: 6 (30%)
Moved: 10 (50%)
Died: 4 (20%)

Had no detectable maternal antibody: N=127
Moved: 6 (5%)
MV at 9 mo: 118 (93%)
Died: 3 (2%)

Still in area: 57 (48%)
Moved: 51 (43%)
Died: 10 (8%)

Outcomes 6 to 9 months

Outcomes 9 to 60 months
Trial II
March-October 2004

Randomised EZ at 4.5 mo
N=482

28 No sample
4 invalid sample

Randomised to No vaccine at 4.5 mo
N=958

10 excluded double registration

N=450 had valid antibody sample

Had detectable maternal antibody: 249
Moved: 5 (2%)
Absent: 7 (3%)
MV elsewhere: 1 (0.4%)
MV at 9 mo: 236 (95%)
Died: 0

Had no detectable maternal antibody: 201
Moved: 4 (2%)
Absent: 2 (1%)
MV elsewhere: 3 (1%)
MV at 9 mo: 191 (95%)
Died: 1 (0.5%)

Still in area: 163 (67%)
Moved: 77 (32%)
Died: 4 (2%)

Still in area: 131 (67%)
Moved: 55 (28)
Died: 10 (5%)

Notes: MV=measles vaccine; mo=month